Shah Amit B. purchased $1K of OTLC
Shah Amit B. (CFO) purchased 20,000 shares of Oncotelic Therapeutics, Inc. (OTLC) at $0.05 on 2026-06-22.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market purchase details (20,000 shares at $0.0500) and resulting holdings (378,837 shares).
Market read
Traders may note the insider buy as a minor sentiment input, but it does not provide new operational or financial guidance.
What to watch
No 10b5-1 plan is stated, but the filing does not disclose intent, timing rationale, or whether other insiders/large holders are acting similarly.
Background
The article is an SEC Form 4 insider transaction disclosure for Oncotelic Therapeutics, Inc. (OTLC).
Ticker impact
Oncotelic Therapeutics CFO Shah Amit B. filed a Form 4 for an open-market purchase of 20,000 shares at $0.0500 on 2026-06-22.
Near-term impact likely limited; any effect would be sentiment-driven and fade unless followed by additional disclosures or operational catalysts.
The transaction is a Form 4 insider purchase with modest dollar value ($1,000) and no 10b5-1 plan, but the filing alone rarely drives sustained repricing without accompanying company-specific news.
Market effects
No sector read-across; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
Insider buys can be discretionary, tax/portfolio-driven, or opportunistic at low prices; a $1,000 purchase may not reflect a strong conviction signal.
Key entities
- issuerOncotelic Therapeutics, Inc.
OTLC, the company whose CFO insider purchase was disclosed on Form 4.
- insiderShah Amit B.
CFO who purchased 20,000 shares in an open-market transaction on 2026-06-22.